Halozyme Therapeutics (NASDAQ:HALO) investors had a great day today, with the stock up 12% on the news that the FDA lifted a clinical hold on its phase 2 trial of PEGPH20 for pancreatic cancer.
The hold had reflected FDA concerns about potential blood clots, but some changes to the trial design and screening sufficiently allayed those fears to allow the trial to proceed, and Halozyme has announced that it plans to enroll additional patients.
In this video, from Thursday's Market Checkup, the Motley Fool's health care-focused investing show, analysts Michael Douglass and David Williamson discuss the changes to the trial and what they think of the stock.
Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.